drugset / Trial / NCT06475443
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of pyrotinib plus capecitabine in HER2-positive breast cancer patients with active brain metastases that have failed ADCs
Timeline
- Start
- 2024-06-15
- Primary completion
- 2026-06-30
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Pyrotinib | Small molecule | — | Oral |